IGF-DES

IGF-1 DES Overview

IGF-1 DES (Des(1-3)IGF-I) is a truncated, naturally occurring analogue of Insulin-like Growth Factor-1. This specific variant is characterized by the absence of the first three amino acids—Glycine, Proline, and Glutamic acid—from the N-terminus of the peptide chain. While standard IGF-I is a primary mediator of growth hormone effects, IGF-1 DES is uniquely concentrated in areas requiring rapid cellular adaptation, such as the human brain and bovine colostrum.

The removal of the N-terminal tripeptide grants IGF-1 DES a biological profile that is ten times more potent than its full-length counterpart. This heightened efficacy is attributed to its inability to bind with IGF-I Binding Proteins (IGFBPs), which normally inhibit the peptide’s interaction with its receptors. Consequently, IGF-1 DES remains highly bioavailable for immediate receptor activation. Research currently explores its utility in addressing muscle-wasting conditions, neurological development in autism, and gastrointestinal barrier integrity.

IGF-1 DES Structure

The structure of IGF-1 DES consists of 67 amino acids in a specific sequence that mimics the core of the 70-amino acid IGF-I molecule. By truncating the N-terminus, the molecule gains a more favorable pharmacokinetic profile for crossing biological membranes and avoiding inhibitory protein sequestration.

Molecular Structure Formula: Carbon 319, Hydrogen 495, Nitrogen 91, Oxygen 96, Sulfur 6

IGF-1 DES Research

Potency and Receptor Interaction

In physiological environments, most IGF-I is rendered inactive by binding proteins (IGFBPs). IGF-1 DES lacks the binding site for these proteins, allowing it to remain in a free, active state. Studies in mammalian cell cultures and animal models have confirmed that because IGF-1 DES does not compete with binding proteins, it can stimulate the IGF-1 receptor at much lower concentrations than native IGF-I. This makes it an exceptionally efficient tool for studying hypertrophy and cellular proliferation.

Neurological Applications and Autism Spectrum Disorder

Research into neurodevelopmental disorders has highlighted a correlation between IGF-I deficiency and autism symptoms. Children with autism often exhibit lower concentrations of this peptide during critical stages of brain growth. IGF-1 DES is of particular interest because its modified structure allows it to cross the blood-brain barrier more effectively than full-length IGF-I. In mouse models, the administration of IGF-1 DES has been shown to reverse behavioral deficits, improve spatial memory, and stabilize synaptic transmission.

Research Category

Primary Scientific Finding

Potential Application

Hypertrophy

10x greater potency in muscle cell growth

Muscle wasting diseases

Bioavailability

Zero affinity for IGF-binding proteins

High-efficiency research dosing

Neurobiology

Enhanced synaptic neuron health

Autism, Fragile X Syndrome

Metabolism

Rapid clearance of blood glucose

Type II Diabetes research

Immunology

Stimulation of neutrophils and macrophages

Infectious disease management

Metabolic Health and Glucose Regulation

Experimental data suggests that IGF-1 DES acts as a rapid-acting anti-hyperglycemic agent. In pig studies, it has demonstrated a superior ability to lower blood sugar and improve nitrogen balance compared to standard insulin or IGF-I, even under calorie-restricted conditions. Researchers believe this makes it a strong candidate for studying the management of metabolic disorders where insulin resistance is a factor.

Oncology and Tissue Repair

In cancer research, IGF-1 DES has been observed to induce differentiation in leukemia and colon cancer cells. By forcing these undifferentiated, rapidly dividing cells to become specialized, the peptide effectively halts tumor proliferation. Additionally, in the field of dermatology, IGF-1 DES supports wound healing by stimulating dermal fibroblasts to create the extracellular matrix necessary for tissue closure, even in environments characterized by high inflammation.

Product Storage

IGF-1 DES is highly sensitive to environmental conditions. The lyophilized powder should be stored in a freezer at -20 degrees Celsius for long-term stability. Once the peptide is reconstituted with a sterile diluent, it must be stored in a refrigerator at 2 to 8 degrees Celsius and protected from light. It is recommended to minimize repeated freeze-thaw cycles to maintain biological activity.

Author and Scientific Recognition

Article Author

This material was researched and edited by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine and a degree in molecular biology.

Scientific Journal Author

Dr. Clemmons is a prominent investigator in the field of endocrinology, specializing in the molecular pathways of growth factors. His research focuses on how IGF-I and its variants promote cellular differentiation and proliferation. He is acknowledged here for his foundational work in the field. Dr. Clemmons has no affiliation with Peptide Sciences and does not endorse the use or sale of this product.

Referenced Citations

• F. J. Ballard, J. C. Wallace, G. L. Francis, L. C. Read, and F. M. Tomas, "Des(1-3)IGF-I: a truncated variant of insulin-like growth factor-I," Int. J. Biochem. Cell Biol., vol. 28, no. 10, pp. 1085-1087, Oct. 1996
• F. M. Tomas, P. C. Walton, F. R. Dunshea, and F. J. Ballard, "IGF-I variants that bind minimally to IGF-binding proteins display more potent and extended hypoglycaemic action compared to native IGF-I in pigs and marmoset monkeys," J. Endocrinol., vol. 155, no. 2, pp. 377-386, Nov. 1997
• P. E. Walton, F. R. Dunshea, and F. J. Ballard, "In vivo actions of IGF analogues with reduced affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness," Prog. Growth Factor Res., vol. 6, no. 2-4, pp. 385-395, 1995
• F. J. Ballard, P. C. Walton, S. Bastian, F. M. Tomas, J. C. Wallace, and G. L. Francis, "Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs," Growth Regul., vol. 3, no. 1, pp. 40-44, Mar. 1993
• R. Camboni, "New experimental treatments for core social domain in autism spectrum disorders," Front. Pediatr., vol. 2, p. 61, 2014
• J. Costales and A. Kolevzon, "The Therapeutic Potential of Insulin-Like Growth Factor-1 in Central Nervous System Disorders," Neurosci. Biobehav. Rev., vol. 63, pp. 207-222, Apr. 2016
• R. Riikonen, "Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children," Int. J. Mol. Sci., vol. 18, no. 10, Sep. 2017
• A. B. Steinmetz, S. A. Stern, S. A. Kohtz, G. Descalzi, and C. M. Alberini, "Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice," J. Neurosci. Off. J. Soc. Neurosci., vol. 38, no. 4, pp. 1015-1029, 24 2018
• D. Ebrahim-Fakhari and M. Sahin, "Autism and the synapse: emerging mechanisms and mechanism-based therapies," Curr. Opin. Neurol., vol. 28, no. 2, pp. 91-102, Apr. 2015
• D. C. Gomedo, M. Beresiewicz, and B. Zablocka, "Neuroprotective effects of short peptides derived from the insulin-like growth factor 1," Neurochem. Int., vol. 51, no. 8, pp. 451-458, Dec. 2007
• M. M. Ramsey, M. M. Adams, O. J. Ariwodola, W. E. Sonntag, and J. L. Weiner, "Functional characterization of des-IGF-1 action at excitatory synapses in the CA1 region of rat hippocampus," J. Neurophysiol., vol. 94, no. 1, pp. 247-254, Jul. 2005
• X. Zhao, B. W. McBride, L. M. Trouten-Radford, and J. H. Burton, "Effects of intramuscular injection of insulin-like growth factor analogues on bovine hydrothermal protein release by neutrophils and basophils by mononuclear cells," J. Endocrinol., vol. 139, no. 2, pp. 245-252, Nov. 1993
• M. E. Yaleman, D. C. Clattey, S. C. Ceyfen-Hughes, V. J. Frost, J. A. Ward, and J. M. Holly, "Cytokines modulate the sensitivity of human fibroblasts to stimulation by insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production," J. Endocrinol., vol. 137, no. 1, pp. 151-159, Apr. 1993
• M. Ramade-Bonnet, F. Gamouille, F. al Alie, M. Roccanilora, J. Menville, and G. Perilliere, "Effects of IGF-I and IGF-I on insulin-like growth factor-I/insulin receptor and its potential IGF-II autocrine loop, promotes the differentiation of human colon cancer cells," Int. J. Cancer, vol. 52, no. 3, pp. 457-473, Oct. 1992
• J Clin Invest. 2004;113(1):25-27. https://doi.org/10.1172/JCI200420660